A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

(Recasts, adds researcher quotes) By Ransdell Pierson NEW YORK, May 1 (Reuters) - Genentech Inc. <DNA.N> and Biogen Idec Inc. <BIIB.O> said on Tuesday their Rituxan cancer drug proved highly effective ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio People with MS who are being treated with ...

BOSTON (MarketWatch) -- A late-stage clinical trial of oncology drug Rituxan failed to show it was effective in treating a certain type of multiple sclerosis, according to Genentech Inc. and Biogen ...

Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window African-American ...

The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert. Calquence (acalabrutinib) and ...

A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).

THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...

May 10, 2007 (Las Vegas) — Rituximab can be safely infused using a rapid 90-minute protocol in patients with non-Hodgkin's lymphoma, according to a presentation made at the annual meeting of the ...

NEW YORK, May 1 (Reuters) - Genentech Inc. and Biogen Idec Inc. said on Tuesday their blockbuster Rituxan drug for lymph cancer was highly effective against multiple sclerosis in a small mid-stage ...